Core Viewpoint - The company, Zhongji Changshou Science (00767.HK), has announced a conditional agreement to acquire a 25% stake in the target company, Zonghe Zhaoxue Cell Bank Limited, for an initial consideration of HKD 300 million, which will be adjusted as specified in the agreement [1] Group 1: Acquisition Details - The acquisition will be financed through the issuance of non-redeemable convertible bonds to the seller, with a maximum amount of HKD 300 million, thus not impacting the company's cash flow [1] - The acquisition is expected to generate positive cash flow for the company in the upcoming fiscal year 2026, based on profit guarantees [1] Group 2: Target Company Overview - The target company operates a premium customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to high-net-worth individuals, particularly in Hong Kong and China [1] - The target company conducts various medical tests, including patented high-standard early screening for circulating tumor cells and 21 other types of medical tests [1] - The target company is involved in research and development of novel cell-based preclinical immunotherapy, including natural killer cell therapies and umbilical cord-derived cell therapies [1] Group 3: Strategic Intent - The board is committed to improving the group's operational and financial conditions by actively seeking potential investment opportunities to diversify the existing business portfolio, expand revenue sources, and enhance shareholder value [2]